UroUpdate

[UroUpdate @uroupdate]

#Update26 Programm ⬇️
Top-Fortbildung, spannende Diskussionen und echtes Update-Wissen für die tägliche Praxis.

https://t.co/Zc8ShmBYr0

#UroUpdate2026 #UroUpdate #Urologie #Fortbildung #MedUpdate #Onkologie #UroOnkologie #CME #Berlin

[onkowissen @onkowissen]

ASCO 2026 | Prostatakarzinom

Prof. Dr. Axel S. Merseburger zieht Bilanz zum diesjährigen Kongress und diskutiert die wichtigsten Entwicklungen beim Prostatakarzinom.

▶️ Jetzt das Wrap-up ansehen.

@amerseburger

#ASCO26 #Prostatakarzinom #Uroonkologie #onkowissentv

[Axel S. Merseburger @amerseburger]

Honored to discuss key messages perioperative #PROTEUS data and the precision-medicine signal from #TALAPRO-3 in HRR-altered mHSPC @ecancer @OncoAlert @EfstathiouEleni @ProfHadaschik @urotoday
https://t.co/NgTgqQ6fq6

[UroUpdate @uroupdate]

#Update26 Programm ⬇️
2. Tag

https://t.co/UuvV3cuolf

#UroUpdate2026 #UroUpdate #Urologie #Fortbildung #MedUpdate #Onkologie #UroOnkologie #CME #Berlin

[UroUpdate @uroupdate]

#Update26 Programm ⬇️
Top-Fortbildung, 1. Tag: spannende Diskussionen

https://t.co/UuvV3cuWaN

#UroUpdate2026 #UroUpdate #Urologie #Fortbildung #MedUpdate #Onkologie #UroOnkologie #CME #Berlin

[UroUpdate @uroupdate]

#Update26 Programm ⬇️
Top-Fortbildung, spannende Diskussionen und echtes Update-Wissen für die tägliche Praxis.

https://t.co/Zc8ShmBYr0

#UroUpdate2026 #UroUpdate #Urologie #Fortbildung #MedUpdate #Onkologie #UroOnkologie #CME #Berlin

[UroUpdate @uroupdate]

2026 Uro Update!
Top-Fortbildung, spannende Diskussionen und echtes Update-Wissen für die tägliche Praxis.

See you in Berlin! 👋

https://t.co/Zc8ShmBqBs

#Update2026 #UroUpdate #Urologie #Fortbildung #MedUpdate #Onkologie #UroOnkologie #CME #Berlin

[touchONCOLOGY @touchONCOLOGY]

🚨 The latest issue of touchREVIEWS in Oncology & Haematology is here!

Explore expert insights on lymphoma, melanoma, lung & biliary cancers, leukaemia, and more.

🧬 Read now: https://t.co/VeeubABMVK

#Oncology #Haematology #CancerResearch #MedicalEducation #Lymphoma #Melanoma

[touchONCOLOGY @touchONCOLOGY]

🌟The future of oncology starts here!

We’re proud to launch touchONCOLOGY Future Leaders 2025—celebrating rising stars
https://t.co/7Ojc7uR5Mw

@andradaturcas @AriRosenbergMD @EMariamidze @EricLanderMD @mnoncology @JArakelyan28092 @poojaghatalia @FoxChaseCancer @BrasilOncologia

[MedscapeLIVE @MedscapeLIVE]

🚨 TODAY! Get the latest updates on mHSPC! 🏥 Dive into novel treatment strategies, strengthen MDT collaboration, and refine care pathways for better patient outcomes. 🎯 Don't miss out! 🔗 Learn more: https://t.co/CDmu7fJHN3 #mHSPC @amerseburger @AlbertoBossial @Ecastromarcos

[Axel S. Merseburger @amerseburger]

Honored to be mentioned by my mentor Prof. Vinata Lokeshwar in her great article on: "Natural history of bladder cancer: Validation of the multiple pathway ..." @OncoAlert @Uroweb @UKSH_KI_HL https://t.co/gLT6gBXN7t

[Axel S. Merseburger @amerseburger]

⚡️PCa Oral Abstract Session⚡️
Final OS w/ TALA + ENZA as 1L Tx in unselected pts with mCRPC in the Ph 3 TALAPRO-2 trial
@neerajaiims @urotoday #medicalavatar #prostatecancer
#GU25 @medudy_com @nataliagandur @bavilima @wandering_gu @DrYukselUrun @alison_tree @CaPsurvivorship @montypal @zklaassen_md @NazliDizman @declangmurphy @AzadOncology @scserendipity1 @UKSH_KI_HL @

[Axel S. Merseburger @amerseburger]

Looking forward meeting @ProfHadaschik @ProfKHerrmann @grimm_mo @BellevilleErik at poster L27 "Prostate Cancer Real World Evidence Registry (PROCARE): Recurrent and metastatic prostate cancer" Study aims to enroll 5,000 patients in Germany #GU25 #ASCOGU25 #mHSPC #mCRPC @OncoAlert

[Axel S. Merseburger @amerseburger]

🚀 Who are the top oncologists leading the digital conversation?
📢 Check out this ranking of digital thought leaders in oncology based on their Twitter following!
📊 Notably, female oncologists highlighted in green! 👇 #MedTwitter #GU25 #ASCOGU25 @brunolarvol @OncoAlert

[Axel S. Merseburger @amerseburger]

First #ASCOGU25 #GU25 voting:
When would you consider HR clinically meaningful in HRR allcomer population
@OncoAlert @neerajaiims @DrYukselUrun @cgratzke @uroupdate @montypal @grimm_mo @declangmurphy @DrChoueiri @dr_coops @ChapinMD @wandering_gu @CaPsurvivorship @brookmans76

[UroUpdate @uroupdate]

#UroUpdate 2025 - Berlin 07.-08. Februar 2025 - safe the Date! #Berlin #Urologie #UroUpdate25
@BDUrologie @GeSRU_de @wulfingc @JulianStruck
@DrHannahArnold @amerseburger @cgratzke
@UroFors_DGU @martin_schostak @PiaPiacere
Anmeldung unter: https://t.co/UuvV3cuWaN

[EAU Edu Platform UROONCO @EAU_Uroonco]

📹 Watch this roundtable discussion with a multi-disciplinary panel moderated by Prof. @amerseburger . They review a difficult metastatic case involving a 72-year-old with biochemical recurrence, oligometastatic disease. Learn more here 👇

https://t.co/vBsMGQeZnQ

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24

LINK TO ARTICLE👇👇👇👇👇👇👇👇
https://t.co/d34qu62Ta3

NOW ON FINAL SESSION of #PROSCA24

The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.

The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.

The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.

Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234

@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin

[Axel S. Merseburger @amerseburger]

Medtronic Hugo RAS is one of the newest robotic system for minimal invasive surgery. We are honored to join the live surgery session #Hugo robotic assisted partial nephrectomy at German robotic annual meeting #Straubingen 👏🏼 @OsmonovDr 💪 #DRUS #DRUS2024 #livestream @UKSH_KI_HL

[Axel S. Merseburger @amerseburger]

Just in 👉 @BJUIjournal in this post hoc analysis of TITAN we show, that patients with the deepest PSA decline derived the greatest benefit in #mHSPC #ProstateCancer
Link: https://t.co/9e8xBOxOCP
@urotoday @OncoAlert @Uroweb